1-6 of 6
Yvette Drew
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Targeted and Shallow Whole-Genome Sequencing Identifies Therapeutic Opportunities in p53abn Endometrial Cancers

Amy Jamieson, Juliana Sobral de Barros, Dawn R. Cochrane, J. Maxwell Douglas, Sameer Shankar, Branden J. Lynch, Samuel Leung, Spencer Martin, Janine Senz, Amy Lum, Yvette Drew, C. Blake Gilks, David G. Huntsman, Jessica N. McAlpine
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (11): 2461–2474.
https://doi.org/10.1158/1078-0432.CCR-23-3689
Published: 03 June 2024
View articletitled, Targeted and Shallow Whole-Genome Sequencing Identifies Therapeutic Opportunities in p53abn Endometrial Cancers
Open the PDF for Targeted and Shallow Whole-Genome Sequencing Identifies Therapeutic Opportunities in p53abn Endometrial Cancers in another window
Includes: Supplementary data
Journal Articles

Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study

Yvette Drew, Jae-Weon Kim, Richard T. Penson, David M. O'Malley, Christine Parkinson, Patricia Roxburgh, Ruth Plummer, Seock-Ah Im, Martina Imbimbo, Michelle Ferguson, Ora Rosengarten, Neeltje Steeghs, Min Hwan Kim, Einav Gal-Yam, Daliah Tsoref, Jae-Hoon Kim, Benoit You, Maja De Jonge, Roy Lalisang, Eelke Gort, Sara Bastian, Kassondra Meyer, Laura Feeney, Nigel Baker, Mei-Lin Ah-See, Susan M. Domchek, Susana Banerjee, for the MEDIOLA Investigators
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (1): 50–62.
https://doi.org/10.1158/1078-0432.CCR-23-2249
Published: 05 January 2024
View articletitled, Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study
Open the PDF for Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study in another window
Includes: Supplementary data
Journal Articles

Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

David S. Hong, Nicole Concin, Ignace Vergote, Johann S. de Bono, Brian M. Slomovitz, Yvette Drew, Hendrik-Tobias Arkenau, Jean-Pascal Machiels, James F. Spicer, Robert Jones, Martin D. Forster, Nathalie Cornez, Christine Gennigens, Melissa L. Johnson, Fiona C. Thistlethwaite, Reshma A. Rangwala, Srinivas Ghatta, Kristian Windfeld, Jeffrey R. Harris, Ulrik Niels Lassen, Robert L. Coleman
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (6): 1220–1228.
https://doi.org/10.1158/1078-0432.CCR-19-2962
Published: 13 March 2020
View articletitled, Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer
Open the PDF for Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors

Rebecca Kristeleit, Geoffrey I. Shapiro, Howard A. Burris, Amit M. Oza, Patricia LoRusso, Manish R. Patel, Susan M. Domchek, Judith Balmaña, Yvette Drew, Lee-may Chen, Tamar Safra, Ana Montes, Heidi Giordano, Lara Maloney, Sandra Goble, Jeff Isaacson, Jim Xiao, Jen Borrow, Lindsey Rolfe, Ronnie Shapira-Frommer
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (15): 4095–4106.
https://doi.org/10.1158/1078-0432.CCR-16-2796
Published: 01 August 2017
View articletitled, A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors
Open the PDF for A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors

Asima Mukhopadhyay, Ahmed Elattar, Aiste Cerbinskaite, Sarah J. Wilkinson, Yvette Drew, Suzanne Kyle, Gerrit Los, Zdenek Hostomsky, Richard J. Edmondson, Nicola J. Curtin
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (8): 2344–2351.
https://doi.org/10.1158/1078-0432.CCR-09-2758
Published: 14 April 2010
View articletitled, Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors
Open the PDF for Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors in another window
Includes: Supplementary data
Journal Articles

Inhibition of Poly(ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma

Rachel A. Daniel, Agata L. Rozanska, Huw D. Thomas, Evan A. Mulligan, Yvette Drew, Deborah J. Castelbuono, Zdenek Hostomsky, E. Ruth Plummer, Alan V. Boddy, Deborah A. Tweddle, Nicola J. Curtin, Steven C. Clifford
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (4): 1241–1249.
https://doi.org/10.1158/1078-0432.CCR-08-1095
Published: 19 February 2009
View articletitled, Inhibition of Poly(ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma
Open the PDF for Inhibition of Poly(ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma in another window
Includes: Supplementary data